Internal Medicine最新文献_第8页

Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia. 日本慢性髓性白血病患者因尼洛替尼而引发的糖尿病

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 Epub Date: 2024-08-28 DOI: 10.2169/internalmedicine.3740-24

Yuichiro Iwamoto, Tomohiko Kimura, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Toshinori Kondo, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideho Wada, Hideaki Kaneto

{"title":"Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia.","authors":"Yuichiro Iwamoto, Tomohiko Kimura, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Masashi Shimoda, Toshinori Kondo, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideho Wada, Hideaki Kaneto","doi":"10.2169/internalmedicine.3740-24","DOIUrl":"10.2169/internalmedicine.3740-24","url":null,"abstract":"Objective This study aimed to examine the risk of diabetes mellitus induced by nilotinib, a second-generation tyrosine kinase inhibitor. Methods This retrospective study included 25 patients with chronic myeloid leukemia (CML) treated with nilotinib at our hospital. Four patients had diabetes mellitus at the start of nilotinib administration (prior DM group), and five patients were newly diagnosed with diabetes mellitus after the start of nilotinib administration (new DM group). Sixteen patients who were not diagnosed with diabetes mellitus were classified into the non-DM group. Changes in the blood glucose and HbA1c levels were evaluated in each group at the time of nilotinib administration and two years later. Results Molecular genetic remission of CML was achieved in 81.8% of patients with diabetes and 72.2% of patients without non-DM group. There were no cases in this study in which nilotinib was changed or discontinued owing to hyperglycemia. There was no difference in the blood glucose levels at the start of nilotinib treatment among the groups. Two years after starting nilotinib, the blood glucose levels in the new DM group [232 (186-296) mg/dL] and prior DM group [168 (123-269) mg/dL] were significantly higher than those in the non-DM group [100 (91-115) mg/dL]. ΔHbA1c levels in the new DM group [1.3 (0.9-2.2) %] and prior DM group [1.6 (0.7-1.7) %] were significantly higher than those in the non-DM group [-0.2 (-0.3-0.1) %]. Conclusion Nilotinib caused diabetes in 23.8% of the participants, but there were no hyperglycemia-related severe adverse events. Therefore, nilotinib may be safely continued with regular monitoring for the development of diabetes after nilotinib administration.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"817-823"},"PeriodicalIF":1.0,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute Respiratory Failure Caused by Lateral Medullary Infarction - An Unknown Condition with Varied Etiology and Requiring Special Vigilance: A Case Series. 髓质外侧梗死引起的急性呼吸衰竭--病因不明，需要特别警惕：病例系列。

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 Epub Date: 2024-09-04 DOI: 10.2169/internalmedicine.3993-24

Ako Miyata, Ryosuke Doijiri, Kohei Takikawa, Takuji Sonoda, Naoya Yamazaki, Shuhei Egashira, Kiyotaka Oi, Kanako Kato, Momoyo Oda, Yosuke Kakisaka, Takahiko Kikuchi

引用次数: 0

Recurrent Vomiting due to Severe Hyponatremic-Hypertensive Syndrome in an Elderly Patient.

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 DOI: 10.2169/internalmedicine.4725-24

Koki Morishita, Kaito Nakamura, Takafumi Kubota, Yusuke Ota, Mirei Nabuchi, Keita Hibako, Yoshimoto Serizawa, Tetsuya Hoshi

引用次数: 0

Role of a Bioelectrical Impedance Analysis in Predicting Anemia among Cardiovascular Disease Patients.

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 DOI: 10.2169/internalmedicine.4824-24

Tomoaki Nishikawa, Akinori Higaki, Yutaro Okada, Rikako Horie, Yasuhisa Nakao, Tomoki Fujisawa, Shigehiro Miyazaki, Yusuke Akazawa, Toru Miyoshi, Hiroshi Kawakami, Haruhiko Higashi, Shunsuke Tamaki, Kazuhisa Nishimura, Katsuji Inoue, Shuntaro Ikeda, Osamu Yamaguchi

{"title":"Role of a Bioelectrical Impedance Analysis in Predicting Anemia among Cardiovascular Disease Patients.","authors":"Tomoaki Nishikawa, Akinori Higaki, Yutaro Okada, Rikako Horie, Yasuhisa Nakao, Tomoki Fujisawa, Shigehiro Miyazaki, Yusuke Akazawa, Toru Miyoshi, Hiroshi Kawakami, Haruhiko Higashi, Shunsuke Tamaki, Kazuhisa Nishimura, Katsuji Inoue, Shuntaro Ikeda, Osamu Yamaguchi","doi":"10.2169/internalmedicine.4824-24","DOIUrl":"https://doi.org/10.2169/internalmedicine.4824-24","url":null,"abstract":"Objective Anemia frequently complicates cardiovascular disease (CVD) and is associated with high mortality rates. A bioelectrical impedance analysis (BIA) is a noninvasive method for measuring human body composition. A direct association between serum hemoglobin (Hb) levels and the extracellular water-to-total body water (ECW/TBW) ratio, as measured by a BIA in patients with diabetes, has been reported. However, the predictive value of the ECW/TBW ratio for detecting anemia in patients with CVD has not been fully elucidated. Methods We conducted a study involving consecutive patients admitted to our cardiology department from January 1, 2021, to December 31, 2022. A BIA was performed once during hospitalization for all patients, whenever possible. The correlation between the Hb level and ECW/TBW ratio was assessed. The predictive accuracy for anemia was evaluated using a receiver operating characteristic (ROC) curve analysis. Results The ECW/TBW ratio was significantly higher in the anemia group than in the non-anemia group (0.41 [0.40, 0.41] vs. 0.39 [0.38, 0.40], p<0.001). The ECW/TBW ratio exhibited a significant negative correlation with Hb, with an R value of 0.57 and a p-value of <0.01. However, this correlation coefficient decreased to 0.45 among subjects with BNP levels ≥200 pg/mL. The area under the ROC curve (AUC) for the ECW/TBW ratio for detecting anemia was 0.83. However, its predictive performance decreased in patients with BNP levels exceeding 200 pg/mL, with an AUC of 0.71. Conclusion The BIA-derived ECW/TBW ratio is a valuable predictor of anemia in patients with CVD, provided BNP levels are not elevated.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary Sclerosing Pneumocytoma: A Case Revealed During 8-year of Follow-up with CT Imaging. 肺硬化性肺细胞瘤：一例通过 CT 成像随访 8 年后发现的病例。

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 Epub Date: 2024-08-08 DOI: 10.2169/internalmedicine.3956-24

Mariko Nishihara, Ryosuke Imai, Takeshi Ushigusa, Tomoaki Nakamura, Clara So, Kohei Okafuji, Atsushi Kitamura, Fumitsugu Kojima, Yutaka Tomishima, Torahiko Jinta, Naoki Nishimura, Toru Bando

引用次数: 0

Real-world Efficacy of Erenumab on Migraine-associated Symptoms and Patient-reported Satisfaction Levels: A Retrospective Study in Japan. 艾伦单抗对偏头痛相关症状和患者报告满意度的实际疗效：日本的一项回顾性研究

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 Epub Date: 2024-08-08 DOI: 10.2169/internalmedicine.4037-24

Keiko Ihara, Nobuyuki Takahashi, Seiya Ohtani, Narumi Watanabe, Kei Ishizuchi, Ryo Takemura, Daiki Tokuyasu, Koji Sekiguchi, Naoki Miyazaki, Shungo Imai, Satoko Hori, Jin Nakahara, Tsubasa Takizawa

{"title":"Real-world Efficacy of Erenumab on Migraine-associated Symptoms and Patient-reported Satisfaction Levels: A Retrospective Study in Japan.","authors":"Keiko Ihara, Nobuyuki Takahashi, Seiya Ohtani, Narumi Watanabe, Kei Ishizuchi, Ryo Takemura, Daiki Tokuyasu, Koji Sekiguchi, Naoki Miyazaki, Shungo Imai, Satoko Hori, Jin Nakahara, Tsubasa Takizawa","doi":"10.2169/internalmedicine.4037-24","DOIUrl":"10.2169/internalmedicine.4037-24","url":null,"abstract":"Objective In randomized clinical trials and real-world studies, calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), including erenumab, have demonstrated efficacy for migraine prevention. However, there have been no real-world studies focusing on erenumab in East Asia that investigated its efficacy on migraine-associated symptoms and patient-reported satisfaction levels. Methods This single-center, observational, retrospective, real-world study examined patients who received at least three doses of erenumab at Keio University Hospital, Tokyo, Japan, between December 2021 and March 2023 as their first CGRP mAb treatment in a real-world setting. The patients were administered 70 mg of erenumab monthly. We assessed changes in monthly migraine days (MMDs), responder rates, migraine-associated symptoms including photophobia, phonophobia, nausea/vomiting, and patient-reported satisfaction levels. In addition, injection site reactions and other adverse events were recorded to investigate safety. Results Nineteen patients were considered eligible for the analysis. At 3 months, erenumab decreased MMDs by 6.6 (95% confidence interval, 2.3-10.8; p<0.01). The 50% responder rate was 42%. A total of 83% (n=15), 56% (n=10), and 71% (n=10) of patients reported either improvement in or disappearance of photophobia, phonophobia, and nausea/vomiting, respectively, and 44% (n=8) and 28% (n=5) answered \"very satisfied\" and \"somewhat satisfied\", respectively, with erenumab treatment, leaving only 28% (n=5) as \"unsatisfied\". Injection site reactions (n=6, 32%) and constipation (n=4, 21%) were frequent adverse events. Conclusion In a real-world setting in Japan, erenumab proved to be effective in not only reducing migraine and headache frequency but also improving migraine-associated symptoms and satisfying the majority of patients.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"825-831"},"PeriodicalIF":1.0,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cryptococcal Prostatic Abscess-images of the Histopathologic Findings. 隐球菌性前列腺脓肿--组织病理学结果图像。

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 Epub Date: 2024-08-10 DOI: 10.2169/internalmedicine.4285-24

Yuya Kawamoto, Hitoshi Honda

引用次数: 0

Rituximab as an Effective Treatment for New-onset Evans Syndrome and Systemic Lupus Erythematosus with Lupus Nephritis.

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 DOI: 10.2169/internalmedicine.4871-24

Koki Matsushita, Yu Nagayoshi, Ryuichi Yoshii, Tomohumi Nakamura, Kengo Kajiwara, Yutaka Kakizoe, Yuichiro Izumi, Masataka Adachi, Masao Tomita, Yukimasa Kohda, Masashi Mukoyama, Hideki Yokoi

引用次数: 0

Neurosyphilis Presenting with Isolated Abducens Nerve Palsy. 一例神经梅毒伴孤立性弓状神经麻痹病例

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 Epub Date: 2024-08-08 DOI: 10.2169/internalmedicine.4098-24

Taiji Mukai, Keiichi Hokkoku, Takatoshi Kitazawa, Hiroshi Oba, Yuki Hatanaka, Masahiro Sonoo, Shunsuke Kobayashi

引用次数: 0

The Predominance of the Upper Lung Fields in Pulmonary Tuberculosis. 肺结核以上肺野为主。

IF 1 4区医学

Internal Medicine Pub Date : 2025-03-15 Epub Date: 2024-08-10 DOI: 10.2169/internalmedicine.4168-24

Jiro Fujita, Tetsu Chinen, Kazutaka Yamaniha, Motoo Baba

引用次数: 0